General Updates

23 July 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 10(c) of Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and Regulation 10(c) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (the “SEBI SBEB Regulations”), we hereby inform that the Nomination and Remuneration Committee at its meeting held today, i.e. on 23 July 2026 has approved the following: (a) taking on record of the in-principle approvals issued by BSE Limited and National Stock Exchange of India Limited for the Cohance Lifesciences Limited – Employee Stock Option Plan, 2026 (the “ESOP 2026”), vide their letters dated 21 July 2026; (b) grant of up to 1,97,48,317 stock options to the eligible employees of the Company under the ESOP 2026; (c) grant of 1,74,843 stock options to the eligible employees of the Company under the Suven Pharmaceuticals Limited – Employee Stock Option Plan – 2023 (the “ESOP 2023”); (d) allotment of 30,190 equity shares of the Company of face value of INR 1 each fully paid-up to the options grantees who have exercised the options vested to them under the ESOP 2023; and (e) with respect to the disclosure made to the stock exchange on 13 March 2026, with respect to grant of 1,98,711 stock options under the ESOP 2023, cancellation of 1,87,703 grants out of such grants. Such cancelled stock options would be available for grant under the ESOP 2023, in accordance with its terms. The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the above grants are annexed herewith as Annexure 1 and the details required to be disclosed under the Regulation 10(c) read with Part E of Schedule I of the SEBI SBEB Regulations are annexed herewith as Annexure 2. Kindly take the above on record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K. Mishra Company Secretary & Compliance Officer Encl: as above Annexure 1 Details under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 A. Details of grant of employee stock options under the ESOP 2026. No Particulars Remarks 1 Brief details of Options Up to 1,97,48,317 employee stock options (“Options”), which may granted be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/- 2 Whether the scheme is in Yes terms of SEBI (SBEB) Regulations, 2021 (if applicable) 3 Total number of shares 1,97,48,317 covered by these options 4 Pricing formula The exercise price per option shall be decided by the board or nomination and remuneration committee and set out in the letter of grant. Provided that in any circumstances, the exercise price shall: (a) not be less than INR 325 (Rupees Three Hundred and Twenty Five only) for any grant that is made within 6 (six) months of the date of receipt of in-principle approval from the stock exchange following the approval of the ESOP 2026 by the shareholders of the Company, provided however that the grant to existing employees of the Company as on the effective date of the ESOP 2026 shall be made within 10 (ten) working days of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, at the exercise price of INR 325 (Rupees Three Hundred and Twenty Five only); or (b) in the case of any grant made after 6 (six) months of the date of receipt of in-principle approval from the stock exchanges following the approval of the shareholders, or any grant to existing employees made after 10 (ten) working days of receipt of in- principle approval from the stock exchanges as set out above, the exercise price shall not be at more than a 20% (twenty percent) discount to the average market price of the shares of the Company over a 21 (twenty-one) trading days’ period preceding one trading day prior to the grant date. 5 Options vested Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 8 (eight) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees. 6 Time within which The exercise period shall be up to 3 years from the date of vesting of option may be exercised options. 7 Options exercised Not applicable 8 Money realized by Not applicable exercise of options 9 The total number of Not applicable shares arising as a result of exercise of option 10 Options lapsed Not applicable 11 Variation of terms of Not applicable options 12 Brief details of The ESOP 2026 was approved by way of postal ballot by the Company significant terms on 13 June 2026. The notice of postal ballot containing the significant terms of ESOP 2026 may be accessed at: https://www.cohance.com/wp-content/uploads/2026/05/Notice-of- Postal-Ballot_May-2026.pdf 13 Subsequent changes or Not applicable cancellation or exercise of such options 14 Diluted earnings per Not applicable share pursuant to issue of equity shares on exercise of options B. Details of grant of employee stock options under the ESOP 2023. No Particulars Remarks 1 Brief details of Options granted Up to 1,74,843 employee stock options (“Options”), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/- 2 Whether the scheme is in terms Yes of SEBI (SBEB) Regulations, 2021 (if applicable) 3 Total number of shares covered The Options, upon exercise, shall result in allotment of 1,74,843 by these options shares. 4 Pricing formula All Options were granted at the exercise price of INR 495. 5 Options vested Options granted shall vest not earlier than minimum period of 1 (one) year and not later than maximum period of 10 (ten) years from the date of grant, subject to conditions as set out in the grant letter as issued to respective employees. The Nomination and Remuneration Committee may at its discretion, subject to applicable laws, change the vesting schedule provided that such change is not detrimental in the interest of the employees. 6 Time within which option may The exercise period shall be up to 3 years from the date of vesting be exercised of options. 7 Options exercised Not applicable 8 Money realized by exercise of Not applicable options 9 The total number of shares Not applicable arising as a result of exercise of option 10 Options lapsed Not applicable 11 Variation of terms of options Not applicable 12 Brief details of significant terms Significant terms of the Options have been given in the ESOP 2023, which can be accessed on the website of the Company. 13 Subsequent changes or The Nomination and Remuneration Committee, at its meeting cancellation or exercise of such held today, also approved the cancellation of up to 17,90,532 options employee stock options under ESOP 2023 pursuant to voluntary surrender by the respective employees; and cancellation of the grant of 1,87,703 stock options previously granted by the Nomination and Remuneration Committee on 13 March 2026. 14 Diluted ear [Showing first 8,000 characters — download PDF for full document]